文献速递高血压

衰弱对强化降压疗效与安全性的影响:SPRINT试验事后分析

The Effect of Frailty on the Efficacy and Safety of Intensive Blood Pressure Control: A Post Hoc Analysis of the SPRINT Trial.
PubMed 文献 · Circulation · 2023-07-04

基于SPRINT试验数据构建衰弱指数,在9306例患者中比较有无衰弱(衰弱指数>0.21)者强化降压的疗效与安全性。中位随访3.22年,衰弱者主要复合终点风险更高,但强化降压的相对与绝对疗效在有无衰弱者间无显著差异(心血管死亡交互P=0.01除外),且未增加严重不良事件风险。

要点

  • 衰弱是心血管高危标志,但强化降压在衰弱者中同样获益。
  • 强化降压未增加衰弱患者的严重不良事件风险。
  • 心血管死亡交互P=0.01需谨慎解读,余终点无显著异质性。

核心结论

  • 衰弱状态是高心血管风险的标志,但衰弱患者与非衰弱患者从强化降压中获益相似,且未增加严重不良事件风险。

研究设计与样本

  • SPRINT试验事后分析,纳入9306例患者(平均年龄67.9±9.4岁),其中2560例(26.7%)存在衰弱(衰弱指数>0.21)。
  • 采用Cox比例风险模型和广义线性模型分别评估相对尺度和绝对尺度上的亚组差异。

主要发现

  • 中位随访3.22年,共观察到561例主要终点事件。
  • 衰弱患者在强化降压组和标准降压组的主要终点风险均显著更高(校正HR分别为2.10 [95%CI 1.59-2.77]和1.85 [95%CI 1.46-2.35])。
  • 强化降压对主要和次要终点的相对疗效在有无衰弱者间无显著差异,除外心血管死亡(衰弱者HR 0.91 [95%CI 0.52-1.60] vs 非衰弱者HR 0.30 [95%CI 0.16-0.59],交互P=0.01)。
  • 绝对尺度上,强化降压疗效在有无衰弱者间亦无显著差异。
  • 衰弱与强化降压治疗的严重不良事件风险之间无显著交互作用。

临床怎么用

  • 衰弱不应作为排除强化降压的理由,衰弱患者可同样从强化降压中获益且安全性可控。
  • 对衰弱患者强化降压时仍需个体化评估,尤其关注心血管死亡风险的异质性信号。

局限性

  • 本研究为SPRINT试验的事后分析,结果需前瞻性研究验证。
  • 衰弱指数基于试验数据构建,可能受限于原始数据的变量范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is associated with an increased risk of all-cause death and cardiovascular events. However, it is uncertain whether frailty modifies the efficacy and safety of intensive blood pressure control. METHODS: Data from SPRINT (Systolic Blood Pressure Intervention Trial) were used to construct a frailty index. Subgroup differences in intensive blood pressure control treatment effects and safety outcomes were measured on a relative and an absolute scale in patients with and without frailty (defined as a frailty index >0.21) using Cox proportional hazard models and generalized linear models, respectively. The primary outcome was a composite of myocardial infarction, acute coronary syndrome without myocardial infarction, stroke, heart failure, and cardiovascular death. RESULTS: A total of 9306 patients (mean age, 67.9±9.4 years), 2560 (26.7%) of whom had frailty, were included in our study. Over a median follow-up of 3.22 years, 561 primary outcomes were observed. Patients with frailty had a significantly higher risk of primary outcome in both the intensive and standard blood pressure control arms (adjusted hazard ratio, 2.10 [95% CI, 1.59-2.77] and 1.85 [95% CI, 1.46-2.35], respectively). Intensive treatment effects on primary and secondary outcomes were not significantly different on a relative scale (except for cardiovascular death [hazard ratio in patients with and without frailty, 0.91 (95% CI, 0.52-1.60) versus 0.30 (95% CI, 0.16-0.59), respectively; Pinteraction=0.01]) or absolute scale. There was no significant interaction between frailty and risks for serious adverse events with intensive treatment. CONCLUSIONS: Frailty status was a marker of high cardiovascular risk. Patients with frailty benefit similarly to other patients from intensive blood pressure control without an increased risk of serious adverse events.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wang, Du, Hua, et al. The Effect of Frailty on the Efficacy and Safety of Intensive Blood Pressure Control: A Post Hoc Analysis of the SPRINT Trial. Circulation. 2023. PMID: 37401465. doi:10.1161/CIRCULATIONAHA.123.064003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。